1. Aithal, G. P., et al. (2011). Case definition and phenotype standardization in drug-induced liver injury. Clinical Pharmacology and Therapeutics, 89, 806–815.
2. Berry, S. M., & Berry, D. A. (2004). Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixture model. Biometrics, 60, 418–426.
3. Cao, D., & He, X. (2011). Statistical analysis of adverse events in randomized clinical trials using SAS. PharmaSUG2011, Paper SP07. http://www.lexjansen.com/pharmasug/2011/SP/PharmaSUG-2011-SP07.pdf .
4. Carragher, R. (2013). A comparison of some methods for detection of safety signals in randomised controlled clinical trials. http://www.sctweb.org/public/meetings/2015/slides/CPS%2013%20-%20Carragher.pdf .
5. Carragher, R. (2015). A comparison of some methods for detection of safety signals in randomised controlled trials. https://strathprints.strath.ac.uk/57234/1/Carragher_SCT_2015_methods_for_detection_of_safety_signals_in_randomised_controlled_trials.pdf .